T. Rowe Price Investment Management, Inc. Immatics N.V. Transaction History
T. Rowe Price Investment Management, Inc.
- $166 Billion
- Q3 2024
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Immatics N.V. stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 7,379,636 shares of IMTX stock, worth $52.4 Million. This represents 0.05% of its overall portfolio holdings.
Number of Shares
7,379,636
Previous 7,433,707
0.73%
Holding current value
$52.4 Million
Previous $86.4 Million
2.52%
% of portfolio
0.05%
Previous 0.05%
Shares
6 transactions
Others Institutions Holding IMTX
# of Institutions
101Shares Held
75.8MCall Options Held
238KPut Options Held
727K-
Rtw Investments, LP New York, NY10MShares$71 Million1.82% of portfolio
-
Wellington Management Group LLP Boston, MA9.68MShares$68.7 Million0.02% of portfolio
-
Perceptive Advisors LLC New York, NY8.09MShares$57.4 Million2.41% of portfolio
-
Baker Bros. Advisors LP New York, NY6.44MShares$45.7 Million0.79% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY3.9MShares$27.7 Million1.61% of portfolio
About Immatics N.V.
- Ticker IMTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,227,000
- Market Cap $541M
- Description
- Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...